Consensus ResMed, Inc.

Stocks

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - NYSE 21:00:02 14/09/2026 BST			5-day change	1st Jan Change
222.99 ^USD	+2.16%		-2.35%	-7.42%

09-10	Resmed Insider Sold Shares Worth $1,110,191, According to a Recent SEC Filing	MT
09-10	Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating	MT

Evolution of the Average Target: ResMed, Inc.

Evolution of the Target Price: ResMed, Inc.

Changes in Analyst Recommendations: ResMed, Inc.

e2d860afdaad6c6.TqN-dy2gbdpOCdimuTOybyQbHq-76llTt8hSUlZvYsc.FvIqPh7qPpc-OZ_j9ArcOUNcS8fhjG1h_JBiYGNYLfQ34DYOeZUi4xZemQ~f2028d308dda21288dbb999b6ce18228

Analysts' recommendations: ResMed, Inc.

09-10	Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating	MT
09-03	Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating	MT
08-31	KeyBanc Adjusts Price Target on ResMed to $267 From $255, Keeps Overweight Rating	MT
08-19	Rothschild & Co Redburn Initiates ResMed at Neutral With $230 Price Target	MT
08-07	Jefferies Adjusts Price Target on ResMed to $220 From $225	MT
08-07	Mizuho Adjusts Price Target on ResMed to $235 From $220	MT
08-07	Morgan Stanley Adjusts Price Target on ResMed to $227 From $229	MT
08-07	KeyBanc Capital Adjusts Price Target on ResMed to $255 From $260	MT
08-07	Piper Sandler Adjusts Price Target on ResMed to $225 From $233	MT
08-07	Baird Adjusts Price Target on ResMed to $213 From $217	MT
08-07	Wells Fargo Adjusts Price Target on ResMed to $215 From $225	MT
08-07	RBC Capital Adjusts PT on ResMed to $244 From $234, Maintains Sector Perform Rating	MT
08-07	Analyst recommendations: Micron Technology, Lockheed Martin, Airbnb, Johnson Controls International, The Allstate Corporation…
07-24	BofA Adjusts Price Target on ResMed to $320 From $310	MT
07-21	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
07-17	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT
07-15	Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating	MT
07-14	Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating	MT
07-13	Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270	MT
07-13	Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34	MT
07-10	Jefferies Adjusts Price Target on ResMed to $225 From $240	MT
07-09	Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight	MT
07-08	ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says	MT
07-08	Wells Fargo Adjusts Price Target on ResMed to $225 From $227	MT
07-08	RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RESMED, INC.					+10.52%
	THERMO FISHER SCIENTIFIC, INC.					+5.14%
	DANAHER CORPORATION					+12.71%
	INTUITIVE SURGICAL, INC.					+26.04%
	BOSTON SCIENTIFIC CORPORATION					+37.62%
	SIEMENS HEALTHINEERS AG					+16.75%
	EDWARDS LIFESCIENCES CORPORATION					+18.06%
	AGILENT TECHNOLOGIES, INC.					+19.18%
	WATERS CORPORATION					+7.98%
	ILLUMINA, INC.					-2.67%
	Average					+15.13%
	Weighted average by Cap.					+14.77%